178 related articles for article (PubMed ID: 30062986)
21. Mass drug administration of ivermectin, diethylcarbamazine, plus albendazole compared with diethylcarbamazine plus albendazole for reduction of lymphatic filariasis endemicity in Papua New Guinea: a cluster-randomised trial.
Laman M; Tavul L; Karl S; Kotty B; Kerry Z; Kumai S; Samuel A; Lorry L; Timinao L; Howard SC; Makita L; John L; Bieb S; Wangi J; Albert JM; Payne M; Weil GJ; Tisch DJ; Bjerum CM; Robinson LJ; King CL
Lancet Infect Dis; 2022 Aug; 22(8):1200-1209. PubMed ID: 35533701
[TBL] [Abstract][Full Text] [Related]
22. Impact of 10 years of diethylcarbamazine and ivermectin mass administration on infection and transmission of lymphatic filariasis.
Ramaiah KD; Das PK; Vanamail P; Pani SP
Trans R Soc Trop Med Hyg; 2007 Jun; 101(6):555-63. PubMed ID: 17374389
[TBL] [Abstract][Full Text] [Related]
23. Community-based trial assessing the impact of annual versus semiannual mass drug administration with ivermectin plus albendazole and praziquantel on helminth infections in northwestern Liberia.
Eneanya OA; Gankpala L; Goss CW; Momolu AT; Nyan ES; Gray EB; Fischer K; Curtis K; Bolay FK; Weil GJ; Fischer PU
Acta Trop; 2022 Jul; 231():106437. PubMed ID: 35405102
[TBL] [Abstract][Full Text] [Related]
24. Safety and efficacy of mass drug administration with a single-dose triple-drug regimen of albendazole + diethylcarbamazine + ivermectin for lymphatic filariasis in Papua New Guinea: An open-label, cluster-randomised trial.
Tavul L; Laman M; Howard C; Kotty B; Samuel A; Bjerum C; O'Brian K; Kumai S; Amuga M; Lorry L; Kerry Z; Kualawi M; Karl S; Makita L; John LN; Bieb S; Wangi J; Weil GJ; Goss CW; Tisch DJ; Pomat W; King CL; Robinson LJ
PLoS Negl Trop Dis; 2022 Feb; 16(2):e0010096. PubMed ID: 35139070
[TBL] [Abstract][Full Text] [Related]
25. The impact of six rounds of single-dose mass administration of diethylcarbamazine or ivermectin on the transmission of Wuchereria bancrofti by Culex quinquefasciatus and its implications for lymphatic filariasis elimination programmes.
Ramaiah KD; Das PK; Vanamail P; Pani SP
Trop Med Int Health; 2003 Dec; 8(12):1082-92. PubMed ID: 14641843
[TBL] [Abstract][Full Text] [Related]
26. The interruption of Onchocerca volvulus and Wuchereria bancrofti transmission by integrated chemotherapy in the Obongi focus, North Western Uganda.
Luroni LT; Gabriel M; Tukahebwa E; Onapa AW; Tinkitina B; Tukesiga E; Nyaraga M; Auma AM; Habomugisha P; Byamukama E; Oguttu D; Katabarwa M; Unnasch TR
PLoS One; 2017; 12(12):e0189306. PubMed ID: 29253862
[TBL] [Abstract][Full Text] [Related]
27. Comparison of the Impact of Annual and Semiannual Mass Drug Administration on Lymphatic Filariasis Prevalence in Flores Island, Indonesia.
Supali T; Djuardi Y; Lomiga A; Nur Linda S; Iskandar E; Goss CW; Miller JP; Weil GJ; Fischer PU
Am J Trop Med Hyg; 2019 Feb; 100(2):336-343. PubMed ID: 30560772
[TBL] [Abstract][Full Text] [Related]
28. Lymphatic filariasis control in Tanga Region, Tanzania: status after eight rounds of mass drug administration.
Simonsen PE; Derua YA; Magesa SM; Pedersen EM; Stensgaard AS; Malecela MN; Kisinza WN
Parasit Vectors; 2014 Nov; 7():507. PubMed ID: 25387483
[TBL] [Abstract][Full Text] [Related]
29. Individual Efficacy and Community Impact of Ivermectin, Diethylcarbamazine, and Albendazole Mass Drug Administration for Lymphatic Filariasis Control in Fiji: A Cluster Randomized Trial.
Hardy M; Samuela J; Kama M; Tuicakau M; Romani L; Whitfeld MJ; King CL; Weil GJ; Grobler AC; Robinson LJ; Kaldor JM; Steer AC
Clin Infect Dis; 2021 Sep; 73(6):994-1002. PubMed ID: 33728462
[TBL] [Abstract][Full Text] [Related]
30. Simultaneous administration of praziquantel, ivermectin and albendazole, in a community in rural northern Ghana endemic for schistosomiasis, onchocerciasis and lymphatic filariasis.
Anto F; Asoala V; Anyorigiya T; Oduro A; Adjuik M; Akweongo P; Aborigo R; Bimi L; Amankwa J; Hodgson A
Trop Med Int Health; 2011 Sep; 16(9):1112-9. PubMed ID: 21689221
[TBL] [Abstract][Full Text] [Related]
31. Community control strategies for scabies: A cluster randomised noninferiority trial.
Hardy M; Samuela J; Kama M; Tuicakau M; Romani L; Whitfeld MJ; King CL; Weil GJ; Schuster T; Grobler AC; Engelman D; Robinson LJ; Kaldor JM; Steer AC
PLoS Med; 2021 Nov; 18(11):e1003849. PubMed ID: 34758017
[TBL] [Abstract][Full Text] [Related]
32. Ivermectin mass drug administration for onchocerciasis elimination: can it reduce the prevalence of scabies in Ethiopia?
Amsalu T; Enbiale W; Manaye N; Ayalew A; Workineh A; De Vries H; Van Griensven J
J Infect Dev Ctries; 2022 Aug; 16(8.1):35S-40S. PubMed ID: 36156500
[TBL] [Abstract][Full Text] [Related]
33. Identifying residual transmission of lymphatic filariasis after mass drug administration: Comparing school-based versus community-based surveillance - American Samoa, 2016.
Sheel M; Sheridan S; Gass K; Won K; Fuimaono S; Kirk M; Gonzales A; Hedtke SM; Graves PM; Lau CL
PLoS Negl Trop Dis; 2018 Jul; 12(7):e0006583. PubMed ID: 30011276
[TBL] [Abstract][Full Text] [Related]
34. Lymphatic filariasis control in Tanzania: infection, disease perceptions and drug uptake patterns in an endemic community after multiple rounds of mass drug administration.
Derua YA; Kisinza WN; Simonsen PE
Parasit Vectors; 2018 Jul; 11(1):429. PubMed ID: 30029675
[TBL] [Abstract][Full Text] [Related]
35. Mapping lymphatic filariasis in Loa loa endemic health districts naïve for ivermectin mass administration and situated in the forested zone of Cameroon.
Beng AA; Esum ME; Deribe K; Njouendou AJ; Ndongmo PWC; Abong RA; Fru J; Fombad FF; Nchanji GT; Amambo G; Gandjui NTV; Biholong B; Nko'Ayissi G; Mbia P; Akame J; Enyong PI; Reid SD; Tougoue JJ; Zhang Y; Wanji S
BMC Infect Dis; 2020 Apr; 20(1):284. PubMed ID: 32299374
[TBL] [Abstract][Full Text] [Related]
36. The impact of ivermectin, diethylcarbamazine citrate, and albendazole mass drug administration on the prevalence of scabies and soil-transmitted helminths in school-aged children in three municipalities in Timor-Leste: a before-after assessment.
Le B; Monteiro MAA; Amaral S; Wand H; Matthews A; Hii SF; Clarke NE; Arkell P; Yan J; Engelman D; Fancourt N; Fernandes JL; Steer A; Kaldor J; Traub R; Francis JR; Nery SV
Lancet Glob Health; 2023 Jun; 11(6):e924-e932. PubMed ID: 37202027
[TBL] [Abstract][Full Text] [Related]
37. Pharmacokinetics, safety, and efficacy of a single co-administered dose of diethylcarbamazine, albendazole and ivermectin in adults with and without Wuchereria bancrofti infection in Côte d'Ivoire.
Edi C; Bjerum CM; Ouattara AF; Chhonker YS; Penali LK; Méité A; Koudou BG; Weil GJ; King CL; Murry DJ
PLoS Negl Trop Dis; 2019 May; 13(5):e0007325. PubMed ID: 31107869
[TBL] [Abstract][Full Text] [Related]
38. Impact of five annual rounds of mass drug administration with ivermectin on onchocerciasis in Sierra Leone.
Koroma JB; Sesay S; Conteh A; Koudou B; Paye J; Bah M; Sonnie M; Hodges MH; Zhang Y; Bockarie MJ
Infect Dis Poverty; 2018 Apr; 7(1):30. PubMed ID: 29628019
[TBL] [Abstract][Full Text] [Related]
39. Impact of repeated annual community directed treatment with ivermectin on loiasis parasitological indicators in Cameroon: Implications for onchocerciasis and lymphatic filariasis elimination in areas co-endemic with Loa loa in Africa.
Wanji S; Chounna Ndongmo WP; Fombad FF; Kengne-Ouafo JA; Njouendou AJ; Longang Tchounkeu YF; Koudou B; Bockarie M; Fobi G; Roungou JB; Enyong PA
PLoS Negl Trop Dis; 2018 Sep; 12(9):e0006750. PubMed ID: 30226900
[TBL] [Abstract][Full Text] [Related]
40. Randomised community-based trial of annual single-dose diethylcarbamazine with or without ivermectin against Wuchereria bancrofti infection in human beings and mosquitoes.
Bockarie MJ; Alexander ND; Hyun P; Dimber Z; Bockarie F; Ibam E; Alpers MP; Kazura JW
Lancet; 1998 Jan; 351(9097):162-8. PubMed ID: 9449870
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
